Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Epstein-Barr virus-specific cytotoxic T lymphocytes + oncogene-specific cytotoxic T lymphocytes
- Development stage
- Unknown
- Lead developer
- Sun Yat-sen University Cancer Center
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Epstein-Barr virus-specific cytotoxic T lymphocytes + oncogene-specific cytotoxic T lymphocytes is an adoptive cell therapy regimen developed by Sun Yat-Sen University Cancer Center for the treatment of nasopharyngeal carcinoma (NPC). This combination therapy involves the infusion of ex vivo expanded T cells that target both Epstein-Barr virus (EBV) latent proteins (such as EBNA1, LMP1, and LMP2) and cellular oncogenes frequently overexpressed in NPC (such as Survivin and hTERT). By simultaneously targeting viral antigens and tumor-associated oncogenes, the therapy aims to minimize immune escape and enhance the eradication of EBV-positive malignant cells. It is currently being investigated in Phase 2 clinical trials for patients with advanced, recurrent, or metastatic nasopharyngeal carcinoma.
- Other names
- EBV-CTLs + oncogene-specific CTLsEBV-specific CTLs + LMP-specific CTLsEBV-specific CTLs + Survivin-specific CTLs + hTERT-specific CTLs
02
Targets
Telomerase reverse transcriptase peptide-human leukocyte antigen complexpMHC (Peptide-MHC complex family)Survivin-HLA (Survivin peptide-HLA complex)Melanoma-associated antigen 3 peptide-human leukocyte antigen complexpMHC-I (Peptide–MHC class I complex)Epstein-Barr virus latent membrane protein 1 peptide-human leukocyte antigen complex
Beyond the preview
Go deeper on Epstein-Barr virus-specific cytotoxic T lymphocytes + oncogene-specific cytotoxic T lymphocytes.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Epstein-Barr virus-specific cytotoxic T lymphocytes + oncogene-specific cytotoxic T lymphocytes.